Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 7/20 | 0.31 |
| ▸ | JAK2 | O60674 | 3/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17582177 | 1.00 | SCN9A (0.35) | SCN9AKDM1AKDM1BRIPK1NTRK1 | |
| SCHEMBL17582091 | 0.87 | KDM1A (0.35) | SCN9AKDM1AKDM1BRIPK1NTRK1 | |
| SCHEMBL17848946 | 0.76 | KDM1A (0.41) | SCN9AKDM1AKDM1BRIPK1NTRK1 | |
| SCHEMBL17821020 | 0.74 | CYP1A2 (0.44) | SCN9ANTRK1JAK2 | |
| SCHEMBL17821019 | 0.74 | CYP1A2 (0.44) | SCN9ANTRK1JAK2 | |
| SCHEMBL18588910 | 0.74 | CYP1A2 (0.44) | SCN9ANTRK1JAK2 | |
| SCHEMBL18588911 | 0.74 | CYP1A2 (0.44) | SCN9ANTRK1JAK2 | |
| Tert-Butyl Formate SCHEMBL28305223 | 0.73 | SCN9A (0.36) | SCN9AKDM1AKDM1BRIPK1NTRK1 | |
| SCHEMBL23825285 | 0.72 | RIPK1 (0.38) | SCN9AKDM1AKDM1BRIPK1NTRK1 | |
| SCHEMBL22013225 | 0.72 | RIPK1 (0.38) | SCN9AKDM1AKDM1BRIPK1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783527-B2 | Indazole ureas and method of use | ABBVIE INC. (US) | 2017-10-10 | — | — | US | disclosed |
| EP-3194404-A1 | INDAZOLE UREAS AND METHOD OF USE | AbbVie Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016044386-A1 | INDAZOLE UREAS AND METHOD OF USE | ABBVIE INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160075692-A1 | Indazole Ureas and Method of Use | ABBVIE INC. (US) | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075692-A1 | Indazole Ureas and Method of Use | SCN8A, SCN7A, SCN3A | SCN9A 12/4885KDM1A 1773/4885KDM1B 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.